SIShunkichi Ikegaki

Shunkichi Ikegaki

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shunkichi Ikegaki has a total of 17 co-authors. Here are the top co-authors by number of shared publications:

  • Goh Ohji

    Division of Infectious Disease Therapeutics, Department of Microbiology and Infectious Diseases, Kobe University Graduate School of Medicine, Kobe, Japan

    2 shared publications
  • Kentaro Iwata

    Division of Infectious Disease Therapeutics, Department of Microbiology and Infectious Diseases, Kobe University Graduate School of Medicine, Kobe, Japan

    2 shared publications
  • Daiki Kano

    Department of Pharmaceutical Sciences, Faculty of Pharmacy and Pharmaceutical Sciences, Fukuyama University, Hiroshima, Japan

    1 shared publication
  • Emiko Saito

    Department of Respiratory Medicine, Hyogo Prefectural Amagasaki General Medical Center, 2-17-77 Higashi Naniwacho, Amagasaki, Hyogo 660-0892, Japan

    1 shared publication
  • Hana Niino

    Integrated Clinical Education Center, Kobe University Hospital , Kobe

    1 shared publication
  • Hiroshi Yamamoto

    Department of Infection Control and Prevention, Graduate School of Medicine, The University of Osaka, Osaka, Japan

    1 shared publication

Latest Publications

  • Fungaemia Caused by the Rare Yeast Starmerella sorbosivorans: A Case Report with Identification via Molecular Phylogenetic Analysis and MALDI-TOF MS

    by Shunkichi Ikegaki, Yuka Nagatsuka, Sayaka Ban, Daiki Kano, Goh Ohji, Hiroshi Yamamoto, Kentaro Iwata, Yuhki Sato

    Invasive yeast infections are associated with high mortality rates, particularly in immunocompromised patients. While most cases of fungaemia are caused by Candida species, rare yeast infections occasionally occur. Here, we present the first documented case of a Starmerella sorbosivorans (= Candida sorbosivorans, homotypic synonym) bloodstream infection in a 39 year-old man with chronic intestinal pseudo-obstruction requiring parenteral nutrition via a tunnelled central venous catheter. The patient presented with fever and was diagnosed with catheter-related bloodstream infection. Initial biochemical identification suggested S. magnoliae, but MALDI-TOF mass spectrometry (MS) failed to provide a definitive identification. Molecular phylogenetic analysis using multiple loci (18S rDNA, internal transcribed spacer [ITS] region, 26S rDNA-D1/D2, TEF1α, and RPB2), combined with proteomic analysis using MALDI-TOF MS, confirmed the isolate as S. sorbosivorans, despite a low ITS sequence similarity (91.3%) to the type strain. The patient was successfully treated with sequential administration of micafungin and liposomal amphotericin B, along with removal of the catheter. Antifungal susceptibility testing revealed low minimum inhibitory concentrations (MICs) for micafungin, amphotericin B, and voriconazole, but high MICs for fluconazole. Our findings emphasise the importance of multilocus sequence analysis for accurate species identification, especially in rare yeast infections caused by uncommon species such as S. sorbosivorans, for which conventional methods may be insufficient. However, to improve the applicability of MALDI-TOF MS in clinical settings, the reference library should be expanded to include rare and emerging yeast species.

  • Open Access

    Emergence of Daptomycin Nonsusceptibility and Treatment Failure in Patients With Corynebacterium striatum Bacteremia

    by Shunkichi Ikegaki, Goh Ohji, Kei Furui Ebisawa, Mitsutaka Tsujimura, Kenichiro Ohnuma, Kentaro Iwata

    We retrospectively reviewed patients with Corynebacterium striatum bacteremia treated with daptomycin. All 11 isolates were initially susceptible to daptomycin, but the emergence of daptomycin nonsusceptibility during treatment and clinical failure occurred in 36% and 45% of patients, respectively.


  • Open Access

    Effect of chest tube position on the success rate of pleurodesis: A retrospective cohort study

    by Tomoyasu Takemura, Shunkichi Ikegaki, Emiko Saito, Hirotaka Matsumoto, Mariko Shinomiya, Yuki Kataoka

    Background: Malignant pleural effusion reduces cancer patients’ quality of life. Some experts have suggested that chest tubes should be directed posteriorly during pleurodesis. We conducted this study to clarify whether a posteriorly positioned chest tube has a better success rate than does an interlobular or anterior one. Methods: We performed a retrospective chart review of patients undergoing pleurodesis between April 2011 and September 2016, and 86 patients were enrolled and divided into two groups based on the chest tube position: posterior (group 1) and others [interlobular and anterior (group 2)]. The primary endpoint was the success rate of pleurodesis, and the secondary endpoint was the complication rate (pain and fever). P < 0.05 was considered to be significant. Results: In total, 66, 20 patients were included in groups 1 and 2, respectively. Complete and partial success was achieved in 57 (86%) and 15 (75%) patients in groups 1 and 2, respectively. The success rates were similar in all groups (p = 0.39). Complications were observed in 51 (77%) and 16 (80%) patients in groups 1 and 2, respectively (p = 0.99). Between the two groups, there was no statistically significant difference in terms of age and sex. Conclusions: In malignant pleural effusion, the success rates of pleurodesis may be similar regardless of the position of the tube. However, this is a retrospective study with insufficient participants. Hence, further investigation is required